Product Information
FENOFIBRATE 130 MG CAPSULE is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.7022 per EA under NDC 68180013106. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 30, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the fenofibrate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
130 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180013106
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021695FDA Approved
11/30/2004
TE Code
AB
On Market Since
2/22/2013
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 130 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 86.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7022 per EA |
|---|---|
| All-time high | $5.1386 (Feb 12, 2014) |
| All-time low | $0.5104 (Sep 20, 2023) |
| 52-week high | $0.8173 |
| 52-week low | $0.6427 |
| Median price | $1.8431 |
| Average price | $2.1947 |
| Largest weekly change | -52.7% (Aug 23, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the fenofibrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 130 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 130 MG CAPSULE, manufactured by Lupin Pharmaceuticals Inc., is $0.7022 per EA (NDC 68180013106), effective Sep 30, 2026.
How has the price of FENOFIBRATE 130 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 130 MG CAPSULE has declined 86.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 130 MG CAPSULE?
Since Nov 28, 2013, the NADAC for FENOFIBRATE 130 MG CAPSULE has ranged from a low of $0.5104 (Sep 20, 2023) to a high of $5.1386 (Feb 12, 2014), with a median of $1.8431 per EA.
Are there cheaper alternatives to FENOFIBRATE 130 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of FENOFIBRATE 130 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FENOFIBRATE 130 MG CAPSULE?
FENOFIBRATE 130 MG CAPSULE (NDC 68180013106) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.